
HALO

BIOPHARMACEUTICALS



Demonstration of Increased Sensitivity with Reduced Trastuzumab Using a 1.5 mm ID Column

286-BIO



PEAK IDENTITIES

LC = Light Chain HC = Heavy Chain

TEST CONDITIONS:

Column: HALO 1000 Å Diphenyl, 2.7 µm, 1.5 x 150 mm Part Number: 9212X-702 **Column:** HALO 1000 Å Diphenyl, 2.7 µm, 2.1 x 150 mm Mobile Phase A: Water/0.1% DFA B: 50% Acetonitrile/50% n-propanol/0.1% DFA Gradient: Time (min) %В 0.0 27 40.0 36 40.1 27 27 45.0 Flow Rate: 0.2 mL/min for 1.5 mm ID 0.4 mL/min for 2.1 mm ID Back Pressure: 252 bar (1.5 mm) 272 bar (2.1 mm) Temperature: 60 °C Injection Volume: 3 µL of 1.0 mg/mL reduced and alkylated trastuzumab Sample Solvent: Water/0.1% TFA LC System: Shimadzu Nexera X2 MS System: ThermoFisher Q Exactive

MS CONDITIONS:

Spray Voltage (kV): 3.8 Capillary temperature: 320 °C Sheath gas: 35 Aux gas: 10 RF lens: 50

A separation of reduced and alkylated Trastuzumab is performed on a HALO 1000 Å Diphenyl column. Switching to a 1.5 mm ID column from the 2.1 mm ID provides a significant increase in sensitivity for the reduced and alkylated Trastuzumab along with a reduced flow rate. This increase in sensitivity can be achieved by using a 1.5 mm ID column in conjunction with optimized tubing post-column which provides a cheaper route for increased sensitivity without the investment into a specialized HPLC system.

AMT_AN_Rev_0

🔁 advancedmaterialstechnology

Made in the USA | halocolumns.com

INNOVATION YOU CAN TRUST, PERFORMANCE YOU CAN RELY ON HALO® and Fused-Core® are registered trademarks of Advanced Materials Technology